Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

ClinicalTrials.gov ID: NCT00140075

Public ClinicalTrials.gov record NCT00140075. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase III, Randomized Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.

Study identification

NCT ID
NCT00140075
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
606 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2000
Primary completion
Jul 31, 2006
Completion
Jul 31, 2006
Last update posted
May 25, 2011

2000 – 2006

United States locations

U.S. sites
54
U.S. states
23
U.S. cities
52
Facility City State ZIP Site status
Pfizer Investigational Site Mobile Alabama 36608
Pfizer Investigational Site Tucson Arizona 85712
Pfizer Investigational Site Bakersfield California 93309
Pfizer Investigational Site Berkeley California 94704
Pfizer Investigational Site Fountain Valley California 92708
Pfizer Investigational Site Fountian Valley California 92708
Pfizer Investigational Site Gilroy California 95020
Pfizer Investigational Site Poway California 92064
Pfizer Investigational Site Soquel California 95073
Pfizer Investigational Site Colorado Springs Colorado 80907
Pfizer Investigational Site Jacksonville Florida 32224
Pfizer Investigational Site Jacksonville Florida
Pfizer Investigational Site Kissimmee Florida 34741
Pfizer Investigational Site Lake Worth Florida 33461
Pfizer Investigational Site Lecanto Florida 34461
Pfizer Investigational Site Miami Florida 33176
Pfizer Investigational Site Miami Shores Florida 33138
Pfizer Investigational Site Port Saint Lucie Florida 34952
Pfizer Investigational Site Tampa Florida 33607
Pfizer Investigational Site Atlanta Georgia 30309
Pfizer Investigational Site Macon Georgia 31201
Pfizer Investigational Site Belleville Illinois 62226
Pfizer Investigational Site Skokie Illinois 60076
Pfizer Investigational Site Baton Rouge Louisiana 70809
Pfizer Investigational Site New Orleans Louisiana
Pfizer Investigational Site Baltimore Maryland 21236
Pfizer Investigational Site Baltimore Maryland 21237
Pfizer Investigational Site Boston Massachusetts 02120
Pfizer Investigational Site Harper Woods Michigan
Pfizer Investigational Site Hattiesburg Mississippi 39401
Pfizer Investigational Site Jackson Mississippi 39202
Pfizer Investigational Site Mount Holly New Jersey 08060
Pfizer Investigational Site Willingboro New Jersey 08046
Pfizer Investigational Site Albuquerque New Mexico 87102
Pfizer Investigational Site Brooklyn New York 11235
Pfizer Investigational Site Great Neck New York 11021'
Pfizer Investigational Site Staten Island New York 10310
Pfizer Investigational Site Burlington North Carolina 27216
Pfizer Investigational Site Greenville North Carolina 27854
Pfizer Investigational Site Raleigh North Carolina 27607
Pfizer Investigational Site Lawton Oklahoma 73505
Pfizer Investigational Site Oklahoma City Oklahoma 73104
Pfizer Investigational Site Lemoyne Pennsylvania 17043
Pfizer Investigational Site Philadelphia Pennsylvania 19106
Pfizer Investigational Site Charleston South Carolina
Pfizer Investigational Site Columbia South Carolina 29201
Pfizer Investigational Site Germantown Tennessee 38138
Pfizer Investigational Site Knoxville Tennessee 37923
Pfizer Investigational Site Corpus Christi Texas 78412
Pfizer Investigational Site Tyler Texas 11937
Pfizer Investigational Site Arlington Virginia 22205
Pfizer Investigational Site Portsmouth Virginia 23704
Pfizer Investigational Site Richmond Virginia 23226
Pfizer Investigational Site Milwaukee Wisconsin 53209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00140075, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 25, 2011 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00140075 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →